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Abstract
Background and objective Data regarding the effects of omega-3 polyunsaturated fatty acids (PUFA) supplementation on
metabolic status of pregnant women are limited. This systematic review and meta-analysis were done based on randomized
controlled trials (RCTs) dealing with the effects of omega-3 PUFA supplementation on glycemic control, lipoproteins, inflam-
mation and oxidative stress in pregnant women.
Methods Following databases were searched for eligible studies published from inception to until 2019: MEDLINE, EMBASE,
Web of Science, PubMed, Scopus, Cochrane Library, and Google scholar. Studies that evaluated the effect of omega-3 PUFA
supplementation on parameters of glycemic control, lipoproteins, inflammation and oxidative stress in pregnant women were
found by using the key MeSH. A study quality assessment was performed using the Cochrane Collaboration risk of bias tool and
heterogeneity between studies was statistically computed using Cochrane’s Q test and I-square (I2). Data were pooled using a
random-effects model and weighted mean difference (WMD) was considered as the overall effect size.
Results No significant effects of omega-3 PUFA supplementation on FPG, insulin, insulin resistance, total cholesterol, triglyc-
erides, LDL-cholesterol, total cholesterol/HDL-cholesterol, interleukin 6 (IL-6), IL-8, and malondialdehyde were found.
However, omega-3 PUFA significantly increased serum concentrations of HDL-cholesterol (WMD: 3.10; 95% CI: 0.18, 6.03)
and reduced C-reactive protein (WMD: -1.85; 95% CI: -2.61, -1.09).
Conclusion Based on the results of this meta-analysis omega-3 PUFA supplementation during pregnancy has a significant
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Introduction
Pregnancy is associated with a variety of physiological chang-
es in maternal metabolism including maternal insulin resis-
tance, dyslipidemia [1], a moderate inflammation [2], and in-
creased oxidative stress [3]. In pregnancies complicated by
obesity, gestational diabetes mellitus (GDM) and pre-
eclampsia these changes are even more expressed [4].
Impaired metabolic function in pregnant women probably al-
so affects fetal growth and development [5]. In recent years,
attention has been focused on maternal supplementation with
different nutrients in order to support additional nutritional
demands during pregnancy, improving mother's health and
fetal development, and preventing metabolic disorders and
adverse pregnancy outcomes [6, 7].
Omega-3 fatty acids are long chain polyunsaturated fatty
acids (PUFA). The most important are alpha linoenic acid
(ALA), eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA).The sources of ALA are vegetable oils like flax-
seed and canola, while EPA and DHA are found in fish oils
[8]. EPA and DHA are important for brain and retinal devel-
opment of fetus [9]. Lower levels of omega-3 PUFA have
been reported in a number of pregnancy complications such
as intrauterine growth restriction (IUGR), pre-eclampsia and
GDM [10]. It has been shown that taking omega-3 PUFA
during pregnancy increased mean gestational length and de-
creased the risk of preterm birth and low birthweight [11].
Zhong et al.[12] in a meta-analysis concluded that omega-3
PUFA supplementation in women with GDM was associated
with decreased fasting plasma glucose (FPG) levels, insulin
resistance and C-reactive protein (CRP) concentrations, but it
did not change the pregnancy outcomes. Since omega-3
PUFA have anti-inflammatory effects and participate in the
regulation of metabolic pathways, a number of studies have
investigated the efficacy of these PUFA onmetabolic status in
different conditions. A meta-analysis by AbuMweis et al. [13]
indicated that taking EPA and DHA supplements decreased
plasma levels of CRP and improved some serum lipoproteins.
Zhang et al. [14], have found in their meta-analysis that
omega-3 PUFA supplementation in overweight and obese
adult's decreased serum triglycerides (TG) but did not change
total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-
cholesterol (HDL-C) levels and FPG.
The efficacy of omega-3 PUFAs supplementation during
pregnancy has not been well stablished and the results of
studies have been inconclusive. Several randomized con-
trolled trials (RCTs) indicated that omega-3 supplementation
in pregnant women might improve some metabolic parame-
ters [15, 16], while several others have not shown beneficial
effects [17, 18]. Discrepancies between studies may be due to
difference in study design, length of treatment, bioavailability
and doses of omega-3 supplements, whether they were per-
formed in healthy or sick pregnant women, previous PUFAs
status of mother and the existence of pregnancy complica-
tions. We have performed a meta-analysis of RCTs to deter-
mine the effects of omega-3 PUFA supplementation on gly-
cemic status, serum lipoproteins concentrations, as well as
biomarkers of inflammation and oxidative stress in healthy
and sick pregnant women.
Methods
Search strategy
Eligible RCTs were identified using Cochrane Library,
Embase, Medline, Scopus, Web of Science, PubMed and
Google scholar databases for relevant articles published from
inception until 2019, and by manually searching the reference
list of the located articles. Studies that evaluated the effects of
omega-3 PUFA supplementation on parameters of glycemic
control, lipoproteins, inflammation and oxidative stress were
found by using MeSH and the following text words: interven-
tion ["omega 3" OR "omega-3" OR "n-3 fatty acid*" OR
"polyunsaturated fatty acid" OR PUFA OR "n-3 oil" OR
"eicosapentaenoic acid" OR "alpha-linolenic acid" OR "alpha
linolenic acid" OR "docosahexaenoic acid" OR "fish oil" OR
"cod liver oil"], outcomes ["glycemic control" OR "glucose"
OR "fasting plasma glucose" OR "fasting blood glucose" OR
"FPG" OR "FBG" OR "FBS" OR "HbA1c" OR "insulin" OR
"HOMA" OR "homeostatic model of insulin resistance" OR
"lipid profile*" OR "lipoprotein" OR "triglyceride*" OR
"cholesterol " OR "LDL" OR "HDL" OR "inflammation"
OR "inflammatory markers" OR "C-Reactive Protein" OR
"CRP" OR "Interleukin*" "IL" OR "oxidative stress" OR
"malondialdehyde" OR "MDA"] and population ["gestation"
OR "pregnancy" OR "pregnant" OR "gestational"].
Additional manual searches including reference lists of related
studies as well as n reviews were reviewed to increase sensi-
tivity of the search strategy. Studies included in this meta-
analysis had to meet the following criteria: 1) original trials,
2) trials on humans, 3) intervention and control groups receiv-
ing omega-3 supplementation, and placebo or control, respec-
tively and 4) the trials that reported mean changes or mean
difference of metabolic parameters with standard deviation
(SD) for the intervention and control groups. The search was
restricted to clinical RCTs on humans and those published in
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English. In this study we did not include trials investigating
the effects of flax seed oil supplementation or combined ther-
apy of fish oil with other nutrients.
Data extraction and quality assessment
Two authors (EA and OA) independently extracted the data
and assessed its quality using standard forms and the
Cochrane Collaboration risk of bias tool [19, 20], respectively.
This tool is based on information on the following domains:
randomization generation, allocation concealment, blinding of
subjects and outcome assessment, incomplete outcome data,
and selective outcome reporting, and other sources of bias.
When there was a disagreement between them, it was resolved
by third author (JH). From eligible studies the following data
were obtained: 1) first authors’ name 2) publication year 3)
age, sex, and anthropologic parameters and/or metabolic pa-
rameters of study participants 4) study location 5) number of
subjects in the intervention and control groups 6) study design
7) duration of the intervention.
Data analysis
Heterogeneity and publication biases
The statistical heterogeneity of the results of the included studies
was tested using chi-square test [21], and quantified by the I2
statistic [22]. Publication bias was assessed by the funnel plot and
tested for statistical significance using the Egger's test [23].
Results
14 Studies with 15 effect sizes were included in this systematic
review and meta-analysis. Flow-diagram of studies selection is
presented in Fig. 1. Included studieswere published from2006 to
2019. 1468 subjects, including 718 controls, were enrolled in
Articles screened by title and
abstract (n=263)
Full text articles assessed for
eligibility (n=23)
Studies included in this study
(n=14)
Article excluded (n=1986) due to duplicate
articles, not English, not randomized
controlled trials, review and not human 
Excluded non-relevant articles (n=240)
Articles excluded (n=9):
1. No relevant outcome reported (n=4)
2. Inappropriate data (n=4)
3. Case report (n=1)
Articles identified through 
electronic database search 
(n=2249)
Fig. 1 Literature search and
review flowchart for selection of
studies
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a: FPG
NOTE: Weights are from random effects analysis
Overall  (I-squared = 71.8%, p = 0.003)
Vahedi L (2018)
Jamilian M  (2017)

























NOTE: Weights are from random effects analysis
Overall  (I-squared = 54.3%, p = 0.053)
Samimi M (2015)
Pellonpera O  (2019)
Jamilian M (2018)























Fig. 2 A-H. Meta-analysis metabolic profiles weighted mean difference
estimates for A) FPG, B) Insulin, C) HOMA-IR, D) Triglycerides, E)
Total cholesterol, F) LDL-cholesterol, G) HDL-cholesterol, H) Total
cholesterol/HDL-cholesterol, I) C-reactive protein, J) Interleukin-6, K)
Interlukin-8, I) Malondialdehyde in the omega-3 and placebo groups
(CI = 95%)
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these studies. Participants were healthy, overweight or obese, and
allergic pregnant women or those with gestational diabetes
mellitus or at risk of depression. Studies were done in
Australia, Norway, Germany, USA, Iran, Spain, New Mexico,
and Finland. The trials used different doses of omega 3 fatty acids
ranging from 1 g/day to 10 ml/day. The duration of intervention
varied from 6 to 25 weeks. Studies reported no significant dif-
ference concerning side effects between intervention and control
groups. TC, LDL-C, HDL-C, TG, TC/HDL-C ratio, FPG, insu-
lin, HOMA-IR, MDA, CRP, IL-6 and IL-8 were measured as
outcome in these studies. General characteristics of included
studies are summarized in Table 1.
c: HOMA-IR
NOTE: Weights are from random effects analysis
Overall  (I-squared = 80.3%, p = 0.002)





















NOTE: Weights are from random effects analysis
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The effects of omega-3 PUFA on glycemic control
Our meta-analysis showed no significant effects of
omega-3 PUFA supplementation on serum concentrations
of FPG [Weighted Mean Difference (WMD): 0.11; 95%
Confidence Interval (CI): -2.52, 2.74)] and insulin
(WMD: -0.79; 95% CI: -2.24, 0.66), and on HOMA-IR
(WMD: -0.56; 95% CI: -1.38, 0.26) (Table 2). Different
e: Total cholesterol
NOTE: Weights are from random effects analysis
Overall  (I-squared = 77.3%, p = 0.000)






























NOTE: Weights are from random effects analysis
Overall  (I-squared = 78.1%, p = 0.001)
Samimi M (2015)
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findings were obtained in subgroup analyses. A signifi-
cant reduction was found in serum levels of FPG follow-
ing omega-3 PUFA supplementation in studies which
lasted ≤ 6 weeks and were performed on patients with
GDM. However, omega-3 PUFA supplementation result-
ed in a significant increase in FPG in studies with a
duration of > 6 weeks and those performed on healthy
subject. On the other hand, omega-3 PUFA supplemen-
tation had a significant effect on reducing insulin level in
studies which lasted ≤ 6 weeks, and those using interven-
tion dosage < 1 g/day which were performed on both
healthy and GDM subjects. However, duration of inter-
vention for > 6 weeks decreased the insulin levels signif-
icantly (Table 3).
g: HDL-cholesterol
NOTE: Weights are from random effects analysis




























NOTE: Weights are from random effects analysis
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The effects of omega-3 PUFA on serum lipoproteins
Supplementation with omega-3 PUFA had no significant
effects on serum concentrations of TC (WMD: 5.36;
95% CI: -2.83, 13.56), TG (WMD: -8.38; 95% CI: -
27.01, 10.24), LDL-C (WMD: 11.98; 95% CI: -0.04,
24.00), and TC/HDL-C (WMD: -0.15; 95% CI: -0.35,
0.06). However, omega-3 PUFA supplementation had a
significant effect on increasing HDL-C levels (WMD:
3.10; 95% CI: 0.18, 6.03). Subgroup analysis demon-
strated that omega-3 PUFA supplementation increased
TC level in studies which used dosage < 1 g/day. All
subgroups showed that TG level was significantly re-
duced after omega-3 PUFA supplementation, except
when dosage was less than 1 g/day. LDL-C level was
significantly increased in studies with the duration > 6
i: C-reactive protein 
Overall  (I-squared = 28.0%, p = 0.244)
Study




















NOTE: Weights are from random effects analysis
Overall  (I-squared = 98.7%, p = 0.000)
)5102(McaihgaH
Mozurkewich EL (b) (2018)
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weeks, when the dosage was ≥ 1 g/day and in those
which were performed on healthy women. However,
findings of the subgroup analysis did not change the
results concerning HDL-C (Table 3).
The effects of omega-3 PUFA on MDA and inflamma-
tory biomarkers
Supplementation with omega-3 PUFA reduced serum CRP
concentrations (WMD: -1.85; 95% CI: -2.61, -1.09), but had
no significant effect on IL-6 (WMD: -5.40; 95% CI: -13.87,
3.08), IL-8 (WMD: 0.09; 95% CI: -0.54, 0.71) and MDA
(WMD: -0.39; 95% CI: -1.43, 0.66) concentrations (Table 2).
Publication bias
Findings from Egger’s regression test demonstrated that there
was no considerable publication bias for FPG (P = 0.051),
Insulin (P = 0.124), HOMA-IR (P = 0.068), TC (P = 0.233),
TG (P = 0.137), LDL-C (P = 0.279), HDL-C (P = 0.085),
TC/HDL (P = 0.350), CRP (P = 0.703), IL-6 (P = 0.841), IL-
8 (P = 0.623), and MDA (P = 0.213).
k: Interlukin-8
Overall  (I-squared = 0.0%, p = 0.855)
Mozurkewich EL (a) (2018)
ID
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Discussion
In this study, for the first time, the data of RCTs with omega-3
PUFA supplementation in pregnant women were analyzed.
This meta-analysis showed that taking omega-3 PUFA sup-
plements during pregnancy might increase HDL-C levels and
decrease serum CRP concentrations.
Effects on parameters of glycemic control and serum
lipoproteins
During the pregnancy different physiologic changes occur
in metabolic status, including increased insulin resistance,
dyslipidemia, increased inflammatory markers and de-
creased antioxidant defense system. Exacerbation of these
changes is supposed to play an important role in pregnancy
complications and negatively affects maternal and infant
outcomes [4, 34]. The findings of this meta-analysis sug-
gest that taking omega-3 PUFA supplements during preg-
nancy significantly increases HDL-C values while does not
affect markers related to glycemic status including FPG,
serum insulin levels, HOMA-IR, but neither TG, TC,
LDL-C and total/HDL-C ratio. Several meta-analyses in-
vestigated the effects of omega-3 PUFAs intake in differ-
ent populations. A meta-analysis by Gao et al.[35], indi-
cated that fish oil supplementation could improve insulin
sensitivity in individuals with metabolic disorders. Zhong
et al.[12] reported that omega-3 PUFA supplementation
decreased FPG and HOMA-IR in women with GDM.
Another study demonstrated that taking EPA and DHA
containing supplements resulted in a significant increase
of both HDL-C and LDL-C levels [13]. A meta-analysis
by Choi et al.[36] indicated that combination therapy with
omega-3 PUFA and statins in patients with dyslipidemia
improved lipid profiles except LDL-C when compared
with statin monotherapy. Abdelhamid et al.[37] found that
increased intake of fish and plant based omega-3 PUFAs in
RCTs that lasted 12 months or more did not change lipid
profiles and that increasing EPA and DHA has little or no
effect on cardiovascular (CV) risk or mortality. Increased
maternal insulin resistance plays a central role in the path-
ogenesis of GDM which is not a rare complication of preg-
nancy [38]. On the other hand, a recent study suggested
that maternal lipid concentrations were associated with off-
spring DNA methylation metabolites and developmental
epigenetic programming which might have an impact on
lifelong disease risk [39]. Decreased insulin sensitivity can
be associated with an altered lipid metabolism [40], and
both are involved in the development of CV disease in
mother and affect offspring health in later life [41, 42].
Omega-3 PUFA may promote insulin sensitivity and lipid
profiles by regulation of transcription factors related to
carbohydrate and lipid metabolism such as peroxisome
proliferator-activated receptor (PPAR) alpha and gamma
and sterol regulatory element binding protein-1c
(SREBP-1c) [43], increased glucose transporter-4
(GLUT-4) and insulin receptor substrate-1 (IRS-1) expres-
sion [44], increased adiponectin secretion and anti-
inflammatory functions [45]. Despite the established fact
that omega-3 PUFA have TG-lowering effects in
Table 2 Effect of omerga-3 on glycemic control, lipid profile, inflammatory biomarkers and oxidative stress biomarkers










Glycemic control FPG 6 0.11 -2.52, 2.74 0.935 71.8% 0.003
Insulin 6 -0.79 -2.24, 0.66 0.285 54.3% 0.053
HOMA-IR 4 -0.56 -1.38, 0.26 0.181 80.3% 0.002
Lipid profile TC 7 5.36 -2.83, 13.56 0.200 77.3% < 0.001
TG 6 -8.38 -27.01, 10.24 0.378 88.4% < 0.001
LDL-C 5 11.98 -0.04, 24.00 0.051 78.1% 0.001
HDL-C 6 3.10 0.18, 6.03 0.038 87.2% < 0.001
TC/HDL 3 -0.15 -0.35, 0.06 0.157 73.0% 0.025
oxidative stress and Inflammatory
biomarkers
CRP 4 -1.85 -2.61, -1.09 < 0.001 28.0% 0.244
IL-6 4 -5.40 -13.87, 3.08 0.212 98.7% < 0.001
IL-8 3 0.09 -0.54, 0.71 0.780 0.0% 0.855
MDA 3 -0.39 -1.43, 0.66 0.470 90.1% < 0.001
FPG, fasting plasma glucose; HOMA IR, homeostasis model assessment of insulin resistance; QUICKI, quantitative insulin-sensitivity check index; TC,
total cholesterol; TG, triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; CRP, C-Reactive Protein; IL, interleukin; MDA,
malondialdehyde
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appropriate doses, conflicting results of different studies
caused uncertainity whether they can prevent CV disease
and events, particularly CV deaths [46]. Recently two stud-
ies were published analyzing the effects of omega-3 PUFA












Effect of omerga-3 on FPG
Study duration (week)
> 6 3 2.38 1.28, 3.48 < 0.001 0.0% 0.432 < 0.001
≤ 6 3 -3. 39 -6.28, -0.49 0.022 24.8% 0.265
Dosage (EPA+DHA)
≥ 1 g/d 2 2.20 -0.02, 4.43 0.053 39.3% 0.199 0.587
< 1 g/d 4 1.50 0.35, 2.66 0.011 81.0% 0.001
Health status
Healthy 3 2.38 1.28, 3.48 < 0.001 0.0% 0.432 < 0.001
GDM 3 -3.39 -6.28, -0.49 0.022 24.8% 0.265
Effect of omerga-3 on insulin
Study duration (week)
> 6 3 -0.31 -0.46, -0.15 < 0.001 29.3% 0.243 0.010
≤ 6 3 -3.11 -5.22, -0.99 0.004 0.0% 0.496
Dosage (EPA+DHA)
≥ 1 g/d 2 1.11 -0.74, 2.96 0.240 0.0% 0.457 0.127
< 1 g/d 4 -0.33 -0.48, -0.18 < 0.001 62.7% 0.045
Health status
Healthy 3 -0.31 -0.46, -0.15 < 0.001 29.3% 0.243 0.010
GDM 3 -3.11 -5.22, -0.99 0.004 0.0% 0.496
Effect of omerga-3 on TG
Study duration (week)
> 6 3 -15.31 -22.79, -7.84 < 0.001 94.9% < 0.001 0.878
≤ 6 3 -14.34 -24.19, -4.49 0.004 52.8% 0.120
Dosage (EPA+DHA)
≥ 1 g/d 1 -35.40 -45.18, -25.61 < 0.001 - - < 0.001
< 1 g/d 5 -2.94 -10.44, 4.56 0.442 75.8% 0.002
Health status
Healthy 3 -15.31 -22.79, -7.84 < 0.001 94.9% < 0.001 0.878
GDM 3 -14.34 -24.19, -4.49 0.004 52.8% 0.120
Effect of omerga-3 on TC
Study duration (week)
> 6 4 1.42 -2.73, 5.58 0.501 87.4% < 0.001 0.561
≤ 6 3 3.80 -3.04, 10.65 0.276 12.6% 0.319
Dosage (EPA+DHA)
≥ 1 g/d 2 -3.52 -8.41, 1.37 0.158 89.5% 0.002 0.001
< 1 g/d 5 8.31 3.14, 13.49 0.002 36.1% 0.181
Health status
Healthy 4 1.42 -2.73, 5.58 0.501 87.4% < 0.001 0.561
GDM 3 3.80 -3.04, 10.65 0.276 12.6% 0.319
Effect of omerga-3 on LDL-C
Study duration (week)
> 6 2 28.82 14.60, 43.04 < 0.001 81.8% 0.019 0.002
≤ 6 3 4.20 -1.39, 9.81 0.141 29.0% 0.245
Dosage (EPA+DHA)
≥ 1 g/d 1 47.95 26.53, 69.36 < 0.001 - - < 0.001
< 1 g/d 4 4.96 -0.40, 10.34 0.070 18.9% 0.296
Health status
Healthy 2 28.82 14.60, 43.04 < 0.001 81.8% 0.019 0.002
GDM 3 4.20 -1.39, 9.81 0.141 29.0% 0.245
Effect of omerga-3 on HDL-C
Study duration (week)
> 6 3 4.96 3.75, 6.16 < 0.001 93.9% < 0.001 0.023
≤ 6 3 2.62 1.01, 4.24 0.001 0.0% 0.672
Dosage (EPA+DHA)
≥ 1 g/d 2 5.23 3.99, 6.48 < 0.001 96.7% < 0.001 0.006
< 1 g/d 4 2.45 0.93, 3.98 0.002 0.0% 0.748
Health status
Healthy 3 4.96 3.75, 6.16 < 0.001 93.9% < 0.001 0.023
GDM 3 2.62 1.01, 4.24 0.001 0.0% 0.672
FPG, fasting plasma glucose; HOMA IR, homeostasis model assessment of insulin resistance; TC, total cholesterol; TG, triglyceride; HDL-C, HDL
cholesterol; LDL-C, LDL cholesterol; GDM, gestational diabetes mellitus
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on serum lipoproteins and CV events on a large number of
subjects. The first study was performed on 15,480 patients
with diabetes who were treated with 1 g/day of omega-3
PUFA and no significant effect on reducing CV events
could be seen [47]. However, in another study on 8,179
patients with elevated triglycerides and either diabetes or
CV disease a much higher dose of 4 g/day resulted with a
significant reduction of CV events [48, 49].
Effects on inflammation and oxidative stress markers
Our meta-analysis showed that omega-3 PUFA supplementation
in pregnant women had a significant effect onCRP plasma levels
but did not improve IL-6, IL-8 and MDA. An earlier meta-
analysis by AbuMweis et al.[13] indicated that EPA and DHA
was effective in reducing CRP levels. Two other meta-analyses
also demonstrated that omega-3 PUFA supplementation was as-
sociated with a significant decrease in inflammatory markers in
patients with T2DM [50] and GDM [12]. According to some
studies fish oil supplementation in patients on hemodialysis re-
duced CRP concentrations without changing IL-6 and TNF-α
levels [51]. Sepidarkis et al. [52] in a meta-analysis suggested
that co-administration of omega-3 PUFA and vitamin E de-
creased MDA but did not improve other markers of oxidative
stress. Ren et al.[53] reported that taking flaxseed and its deriv-
atives could not improveCRP levels except in obese populations.
Another study reported that omega-3 PUFA supplementation did
not affect CRP levels in patients with chronic kidney disease
[54]. During pregnancy inflammatory state and oxidative stress
are associated with an imbalance between angiogenic and
antiangiogenic factors which leads to low-flow uteroplacental
circulation and chronic fetal hypoxia. This consequently in-
creases the risk of placental abruption, premature rupture of
membranes, fetal growth restriction, preeclampsia and stillbirth
[55, 56]. Modulation of maternal immune system function and
anti-oxidant defense system may be a potential therapeutic target
to reduce these adverse pregnancy outcomes [57, 58]. Probable
mechanisms by which omega-3 PUFA might achieve anti-
inflammatory and antioxidant effects most probably include sup-
pression of generation of pro-inflammatory eicosanoids by com-
petition for active sites of cyclooxygenase and lipoxygenase en-
zymes, inhibition of nuclear factor kappa B (NF-kB), decreased
cytokines production, activation of anti-inflammatory transcrip-
tion factor PPAR gamma, modulation of cell membrane phos-
pholipids composition, participating in nitric oxide (NO) synthe-
sis, increasing resolvins and protectins production and restored
antioxidant capacity [59–61].
This meta-analysis has some limitations. One of the
most important is that subjects in the included studies
had different clinical characteristics, and the studies
were performed on healthy, overweight or obese, and
allergic pregnant women as well as those with gesta-
tional diabetes mellitus or at risk of depression which
might have an influence on the results. Moreover, due
to the heterogeneity between the studies concerning var-
iations in duration of omega-3 PUFA intake, the dosage
and frequency of omega-3 PUFA used, the results of
this meta-analysis should be interpreted with caution.
The number of studies and sample size of participant's
that finally were included in this meta-analysis was rel-
atively low.
Conclusions
Based on the results of this meta-analysis, it could be conclud-
ed that omega-3 PUFA supplementation during pregnancy
has a significant beneficial effect on HDL-C and CRP levels.
Therefore, omega-3 PUFA intake might play an indirect role
in improved pregnancy outcomes due to its effect on HDL-C
and CRP levels.
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